• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Emergent BioSolutions Turns Bearish, So Beware

A break in a key support level could precipitate further declines in the life sciences company's shares.
By BRUCE KAMICH
Mar 04, 2021 | 08:27 AM EST
Stocks quotes in this article: EBS, JNJ, AZN

In his first Executive Decision segment of "Mad Money" Wednesday, host Jim Cramer spoke with Bob Kramer, president and CEO of Emergent BioSolutions (EBS) , a life sciences company playing a key part in the vaccine manufacturing process.

Kramer said his team has done an amazing job over the past year, ramping up manufacturing for both the Johnson & Johnson (JNJ) and AstraZeneca (AZN) vaccines from zero to almost 100 million doses a month. Emergent's manufacturing lines are now running 24/7, he said, and the company is on track for one billion Covid vaccine doses annually.

Kramer said while some investors believe the company's growth will slow once the world is vaccinated for Covid, Emergent has many other businesses that are ramping up nicely to pick up any slack.

Let's check if the charts are ramping up, too.

We last looked at EBS on Jan. 12 and wrote at that time, "In this updated daily Point and Figure chart of EBS, below, we used a traditional even-dollar scaling method. Here, a trade at $104 will be a double-top breakout and could open the way to further gains. A price target of $128 is being projected." Let's check again.

In this updated daily bar chart of EBS, below, we can see that prices got very close to our $128 target by the middle of February. Prices quickly turned lower. EBS is now trading below the cresting 50-day moving average line and just below the rising 200-day moving average line. The daily On-Balance-Volume (OBV) line shows strength from December to the middle of February. The OBV line has turned weak/bearish in the past three weeks and tells us that sellers of EBS are now more aggressive. The Moving Average Convergence Divergence (MACD) oscillator quickly turned lower in the middle of February and is now below the zero line for an outright sell signal.

In this weekly bar chart of EBS, below, we see a weak picture. Prices are below the 40-week moving average line. The weekly OBV has started to turn lower and the MACD oscillator is crossing to the downside for a take profit sell signal.

In this daily Point and Figure chart of EBS, below, we can see that the software is projecting an upside price target in the $120 area. The chart also shows that a trade at $92.69 could weaken the picture.

In this second Point and Figure chart of EBS, below, we used weekly price data. Here the software is projecting a downside price target in the $54 area.

Bottom line strategy: Despite the positive fundamental story EBS looks like it will retest the December/January lows. A break of the support around $80 will likely precipitate further declines. Sell any remaining longs.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Life Sciences | Pharmaceuticals | Mad Money | Executive Interview | Real Money | Coronavirus

More from Stocks

Market Mistrust May Make for a Move Higher

James "Rev Shark" DePorre
May 26, 2022 4:41 PM EDT

This lack of faith in the market could help put more pressure on the upside, here's how.

When the Markets Are a Game of Risk, Keep This Fund in Your Quiver

Mark Abssy
May 26, 2022 3:15 PM EDT

This ETF manages risk in a nuanced way.

At Some Point, Commodities Find Balance, Too

Maleeha Bengali
May 26, 2022 2:23 PM EDT

Don't forget about the importance of timing and demand as we look at wild moves in oil from the Covid lows to now.

AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed

Bruce Kamich
May 26, 2022 2:19 PM EDT

Should you be a buyer?

Why I Would Be a Buyer of United Microelectronics

Bruce Kamich
May 26, 2022 1:14 PM EDT

Take a look at this chipmaker's charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login